{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:53:53Z","timestamp":1785873233630,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"DOI":"10.7759\/cureus.83142","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T19:58:08Z","timestamp":1745870288000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Vonoprazan Triple Therapy, Bismuth Quadruple Therapy, and Amoxicillin Therapy for Helicobacter pylori Infection: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Zafeer-ul-Hassan","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad Hassan","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shama Shahid","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana Asjad","family":"Dilshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mars Christian Aragon","family":"Sta Ines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1339750","article-title":"Effects of Helicobacter pylori infection on intestinal microbiota, immunity and colorectal cancer risk","volume":"14","author":"Engelsberger V","year":"2024","unstructured":"Engelsberger V, Gerhard M, Mej\u00edas-Luque R. Effects of Helicobacter pylori infection on intestinal microbiota, immunity and colorectal cancer risk. Front Cell Infect Microbiol. 2024, 14:1339750. 10.3389\/fcimb.2024.1339750","journal-title":"Front Cell Infect Microbiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2023.300","article-title":"Predicting Helicobacter pylori infection from endoscopic features","volume":"39","author":"Seo JY","year":"2024","unstructured":"Seo JY, Ahn JY, Kim S, et al.. Predicting Helicobacter pylori infection from endoscopic features. Korean J Intern Med. 2024, 39:439-447. 10.3904\/kjim.2023.300","journal-title":"Korean J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0318937","article-title":"Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: a systematic review and network meta-analysis","volume":"20","author":"Wei J","year":"2025","unstructured":"Wei J, Zheng Z, Wang X, et al.. Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: a systematic review and network meta-analysis. PLoS One. 2025, 20:e0318937. 10.1371\/journal.pone.0318937","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i28.4076","article-title":"Helicobacter pylori infection: beyond gastric manifestations","volume":"26","author":"Santos ML","year":"2020","unstructured":"Santos ML, de Brito BB, da Silva FA, et al.. Helicobacter pylori infection: beyond gastric manifestations. World J Gastroenterol. 2020, 26:4076-4093. 10.3748\/wjg.v26.i28.4076","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-021-00146-4","article-title":"Helicobacter pylori infection causes both protective and deleterious effects in human health and disease","volume":"22","author":"Miller AK","year":"2021","unstructured":"Miller AK, Williams SM. Helicobacter pylori infection causes both protective and deleterious effects in human health and disease. Genes Immun. 2021, 22:218-226. 10.1038\/s41435-021-00146-4","journal-title":"Genes Immun"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092191","article-title":"Helicobacter pylori infection and extragastric diseases-a focus on the central nervous system","volume":"10","author":"Baj J","year":"2021","unstructured":"Baj J, Forma A, Flieger W, et al.. Helicobacter pylori infection and extragastric diseases-a focus on the central nervous system. Cells. 2021, 10:10.3390\/cells10092191","journal-title":"Cells"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1143969","article-title":"The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori","volume":"14","author":"Zhang Z","year":"2023","unstructured":"Zhang Z, Liu F, Ai F, et al.. The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori. Front Pharmacol. 2023, 14:1143969. 10.3389\/fphar.2023.1143969","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102529","article-title":"10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: a randomised, open-label, non-inferiority trial","volume":"70","author":"Yang EH","year":"2024","unstructured":"Yang EH, Chen WY, Chiang HC, et al.. 10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: a randomised, open-label, non-inferiority trial. EClinicalMedicine. 2024, 70:102529. 10.1016\/j.eclinm.2024.102529","journal-title":"EClinicalMedicine"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00449-x","article-title":"Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications","volume":"18","author":"Tshibangu-Kabamba E","year":"2021","unstructured":"Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2021, 18:613-629. 10.1038\/s41575-021-00449-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12299","article-title":"Helicobacter pylori and antibiotic resistance, a continuing and intractable problem","volume":"21","author":"Hu Y","year":"2016","unstructured":"Hu Y, Zhang M, Lu B, Dai J. Helicobacter pylori and antibiotic resistance, a continuing and intractable problem. Helicobacter. 2016, 21:349-363. 10.1111\/hel.12299","journal-title":"Helicobacter"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12843","article-title":"Management of Helicobacter pylori infection","volume":"7","author":"Aumpan N","year":"2023","unstructured":"Aumpan N, Mahachai V, Vilaichone RK. Management of Helicobacter pylori infection. JGH Open. 2023, 7:3-15. 10.1002\/jgh3.12843","journal-title":"JGH Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-020-01723-6","article-title":"Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility","volume":"55","author":"Okubo H","year":"2020","unstructured":"Okubo H, Akiyama J, Kobayakawa M, et al.. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J Gastroenterol. 2020, 55:1054-1061. 10.1007\/s00535-020-01723-6","journal-title":"J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01991-5","article-title":"Vonoprazan: a review in Helicobacter pylori infection","volume":"84","author":"Shirley M","year":"2024","unstructured":"Shirley M. Vonoprazan: a review in Helicobacter pylori infection. Drugs. 2024, 84:319-327. 10.1007\/s40265-023-01991-5","journal-title":"Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000519413","article-title":"The ideal Helicobacter pylori treatment for the present and the future","volume":"103","author":"Suzuki S","year":"2022","unstructured":"Suzuki S, Kusano C, Horii T, Ichijima R, Ikehara H. The ideal Helicobacter pylori treatment for the present and the future. Digestion. 2022, 103:62-68. 10.1159\/000519413","journal-title":"Digestion"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10010013","article-title":"European registry on Helicobacter pylori management: effectiveness of first and second-line treatment in Spain","volume":"10","author":"Caldas M","year":"2020","unstructured":"Caldas M, P\u00e9rez-Aisa \u00c1, Castro-Fern\u00e1ndez M, et al.. European registry on Helicobacter pylori management: effectiveness of first and second-line treatment in Spain. Antibiotics (Basel). 2020, 10:13. 10.3390\/antibiotics10010013","journal-title":"Antibiotics (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001594","article-title":"Joint ESPGHAN\/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016)","volume":"64","author":"Jones NL","year":"2017","unstructured":"Jones NL, Koletzko S, Goodman K, et al.. Joint ESPGHAN\/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017, 64:991-1003. 10.1097\/MPG.0000000000001594","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332804","article-title":"Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg)","volume":"74","author":"Olmedo L","year":"2024","unstructured":"Olmedo L, Calvet X, Gen\u00e9 E, et al.. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). Gut. 2024, 74:15-25. 10.1136\/gutjnl-2024-332804","journal-title":"Gut"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-004-1424-8","article-title":"Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population","volume":"39","author":"Shimoyama T","year":"2004","unstructured":"Shimoyama T, Fukuda S, Mikami T, Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J Gastroenterol. 2004, 39:927-930. 10.1007\/s00535-004-1424-8","journal-title":"J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2008.00615.x","article-title":"Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study","volume":"13","author":"Kim SY","year":"2008","unstructured":"Kim SY, Lee SW, Jung SW, et al.. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study. Helicobacter. 2008, 13:282-287. 10.1111\/j.1523-5378.2008.00615.x","journal-title":"Helicobacter"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02166.x","article-title":"Amoxicillin resistance with beta-lactamase production in Helicobacter pylori","volume":"39","author":"Tseng YS","year":"2009","unstructured":"Tseng YS, Wu DC, Chang CY, et al.. Amoxicillin resistance with beta-lactamase production in Helicobacter pylori. Eur J Clin Invest. 2009, 39:807-812. 10.1111\/j.1365-2362.2009.02166.x","journal-title":"Eur J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021, 134:103-112. 10.1016\/j.jclinepi.2021.02.003","journal-title":"J Clin Epidemiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2020.739","article-title":"A comparison of patient, intervention, comparison, outcome (PICO) to a new, alternative clinical question framework for search skills, search results, and self-efficacy: a randomized controlled trial","volume":"108","author":"Kloda LA","year":"2020","unstructured":"Kloda LA, Boruff JT, Cavalcante AS. A comparison of patient, intervention, comparison, outcome (PICO) to a new, alternative clinical question framework for search skills, search results, and self-efficacy: a randomized controlled trial. J Med Libr Assoc. 2020, 108:185-194. 10.5195\/jmla.2020.739","journal-title":"J Med Libr Assoc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010606","article-title":"Conflicts of interest and spin in reviews of psychological therapies: a systematic review","volume":"6","author":"Lieb K","year":"2016","unstructured":"Lieb K, von der Osten-Sacken J, Stoffers-Winterling J, Reiss N, Barth J. Conflicts of interest and spin in reviews of psychological therapies: a systematic review. BMJ Open. 2016, 6:e010606. 10.1136\/bmjopen-2015-010606","journal-title":"BMJ Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1172-8","article-title":"Risk of bias tools in systematic reviews of health interventions: an analysis of PROSPERO-registered protocols","volume":"8","author":"Farrah K","year":"2019","unstructured":"Farrah K, Young K, Tunis MC, Zhao L. Risk of bias tools in systematic reviews of health interventions: an analysis of PROSPERO-registered protocols. Syst Rev. 2019, 8:1-9. 10.1186\/s13643-019-1172-8","journal-title":"Syst Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.01.006","article-title":"Applying Grading of Recommendations Assessment, Development and Evaluation (GRADE) to diagnostic tests was challenging but doable","volume":"67","author":"Gopalakrishna G","year":"2014","unstructured":"Gopalakrishna G, Mustafa RA, Davenport C, et al.. Applying Grading of Recommendations Assessment, Development and Evaluation (GRADE) to diagnostic tests was challenging but doable. J Clin Epidemiol. 2014, 67:760-768. 10.1016\/j.jclinepi.2014.01.006","journal-title":"J Clin Epidemiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/17439760.2016.1262613","article-title":"Thematic analysis","volume":"12","author":"Clarke V","year":"2016","unstructured":"Clarke V, Braun V. Thematic analysis. J Positive Psychol. 2016, 12:297-298. 10.1080\/17439760.2016.1262613","journal-title":"J Positive Psychol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/alr.20095","article-title":"Development of an evidence-based review with recommendations using an online iterative process","volume":"1","author":"Rudmik L","year":"2011","unstructured":"Rudmik L, Smith TL. Development of an evidence-based review with recommendations using an online iterative process. Int Forum Allergy Rhinol. 2011, 1:431-437. 10.1002\/alr.20095","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial","volume":"163","author":"Chey WD","year":"2022","unstructured":"Chey WD, M\u00e9graud F, Laine L, L\u00f3pez LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022, 163:608-619. 10.1053\/j.gastro.2022.05.055","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study","volume":"65","author":"Murakami K","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016, 65:1439-1446. 10.1136\/gutjnl-2015-311304","journal-title":"Gut"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002696","article-title":"Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: a randomized controlled trial","volume":"136","author":"Chen S","year":"2023","unstructured":"Chen S, Shen W, Liu Y, Dong Q, Shi Y. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: a randomized controlled trial. Chin Med J (Engl). 2023, 136:1690-1698. 10.1097\/CM9.0000000000002696","journal-title":"Chin Med J (Engl)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.55519\/JAMC-S4-12110","article-title":"Efficacy and cost-effectiveness, comparison of 7-days vonoprazan versus 14-days esomeprazole based triple therapies for treating Helicobacter pylori infection in Pakistani population: a randomized clinical trial","volume":"35","author":"Waqar F","year":"2023","unstructured":"Waqar F, Noor M, Farhat K, Ali S, Haider E, Fatima Gillani SF. Efficacy and cost-effectiveness, comparison of 7-days vonoprazan versus 14-days esomeprazole based triple therapies for treating Helicobacter pylori infection in Pakistani population: a randomized clinical trial. J Ayub Med Coll Abbottabad. 2023, 35:S746-S751. 10.55519\/JAMC-S4-12110","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13133","article-title":"Vonoprazan dual or triple therapy versus bismuth-quadruple therapy as first-line therapy for Helicobacter pylori infection: a three-arm, randomized clinical trial","volume":"29","author":"Cheung KS","year":"2024","unstructured":"Cheung KS, Lyu T, Deng Z, et al.. Vonoprazan dual or triple therapy versus bismuth-quadruple therapy as first-line therapy for Helicobacter pylori infection: a three-arm, randomized clinical trial. Helicobacter. 2024, 29:e13133. 10.1111\/hel.13133","journal-title":"Helicobacter"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15700","article-title":"Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori","volume":"36","author":"Bunchorntavakul C","year":"2021","unstructured":"Bunchorntavakul C, Buranathawornsom A. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. J Gastroenterol Hepatol. 2021, 36:3308-3313. 10.1111\/jgh.15700","journal-title":"J Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17070","article-title":"Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication","volume":"56","author":"Ang D","year":"2022","unstructured":"Ang D, Koo SH, Chan YH, et al.. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther. 2022, 56:436-449. 10.1111\/apt.17070","journal-title":"Aliment Pharmacol Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.47391\/JPMA.9545","article-title":"Therapeutic efficacy and drug safety comparison of one-week Vonoprazan triple therapy with two-weeks Esomeprazole triple therapy in Helicobacter pylori infection: findings from a single-centre randomized clinical trial in population of Pakistan","volume":"74","author":"Waqar F","year":"2024","unstructured":"Waqar F, Noor M, Haider E, Farhat K, Ali S, Fatime Gilani SF. Therapeutic efficacy and drug safety comparison of one-week Vonoprazan triple therapy with two-weeks Esomeprazole triple therapy in Helicobacter pylori infection: findings from a single-centre randomized clinical trial in population of Pakistan. J Pak Med Assoc. 2024, 74:432-435. 10.47391\/JPMA.9545","journal-title":"J Pak Med Assoc"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13019","article-title":"Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan","volume":"28","author":"Ratana-Amornpin S","year":"2023","unstructured":"Ratana-Amornpin S, Sanglutong L, Eiamsitrakoon T, Siramolpiwat S, Graham DY, Mahachai V. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter. 2023, 28:e13019. 10.1111\/hel.13019","journal-title":"Helicobacter"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12690","article-title":"Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial","volume":"25","author":"Kakiuchi T","year":"2020","unstructured":"Kakiuchi T, Mizoe A, Yamamoto K, et al.. Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial. Helicobacter. 2020, 25:e12690. 10.1111\/hel.12690","journal-title":"Helicobacter"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16679","article-title":"Comparison of vonoprazan bismuth-containing triple therapy with quadruple therapy in Helicobacter pylori-infected treatment-naive patients: a prospective multicenter randomized controlled trial","volume":"39","author":"Liang JW","year":"2024","unstructured":"Liang JW, Xiong S, Jia YG, et al.. Comparison of vonoprazan bismuth-containing triple therapy with quadruple therapy in Helicobacter pylori-infected treatment-naive patients: a prospective multicenter randomized controlled trial. J Gastroenterol Hepatol. 2024, 39:2293-2298. 10.1111\/jgh.16679","journal-title":"J Gastroenterol Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13129","article-title":"Seven-day vonoprazan-based triple therapy as first-line Helicobacter pylori treatment in comparison with extended sequential therapy: a randomized controlled trial","volume":"29","author":"Chiu YT","year":"2024","unstructured":"Chiu YT, Lee FJ, Kuo CY, et al.. Seven-day vonoprazan-based triple therapy as first-line Helicobacter pylori treatment in comparison with extended sequential therapy: a randomized controlled trial. Helicobacter. 2024, 29:e13129. 10.1111\/hel.13129","journal-title":"Helicobacter"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12456","article-title":"Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial","volume":"23","author":"Sue S","year":"2018","unstructured":"Sue S, Ogushi M, Arima I, et al.. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter. 2018, 23:e12456. 10.1111\/hel.12456","journal-title":"Helicobacter"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0374-x","article-title":"Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study","volume":"33","author":"Sakurai Y","year":"2016","unstructured":"Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study. Adv Ther. 2016, 33:1519-1535. 10.1007\/s12325-016-0374-x","journal-title":"Adv Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13077","article-title":"Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication","volume":"29","author":"Chen J","year":"2024","unstructured":"Chen J, Zhang Y, Min H, et al.. Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication. Helicobacter. 2024, 29:e13077. 10.1111\/hel.13077","journal-title":"Helicobacter"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002255","article-title":"Hybrid, high-dose dual and bismuth quadruple therapies for first-line treatment of Helicobacter pylori infection in Taiwan: a multicenter, open-label, randomized trial","volume":"118","author":"Hsu PI","year":"2023","unstructured":"Hsu PI, Chen KY, Tai WC, et al.. Hybrid, high-dose dual and bismuth quadruple therapies for first-line treatment of Helicobacter pylori infection in Taiwan: a multicenter, open-label, randomized trial. Am J Gastroenterol. 2023, 118:1184-1195. 10.14309\/ajg.0000000000002255","journal-title":"Am J Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.4103\/njcp.njcp_89_22","article-title":"The efficacy of bismuth quadruple therapy, sequential therapy, and hybrid therapy as a first-line regimen for Helicobacter pylori infection compared with standard triple therapy","volume":"25","author":"Koroglu M","year":"2022","unstructured":"Koroglu M, Ayvaz MA, Ozturk MA. The efficacy of bismuth quadruple therapy, sequential therapy, and hybrid therapy as a first-line regimen for Helicobacter pylori infection compared with standard triple therapy. Niger J Clin Pract. 2022, 25:1535-1541. 10.4103\/njcp.njcp_89_22","journal-title":"Niger J Clin Pract"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13079","article-title":"Long-term effects of fecal microbiota transplantation on gut microbiota after Helicobacter pylori eradication with bismuth quadruple therapy: a randomized controlled trial","volume":"29","author":"Zhao JT","year":"2024","unstructured":"Zhao JT, Zhang Y, Wang XW, et al.. Long-term effects of fecal microbiota transplantation on gut microbiota after Helicobacter pylori eradication with bismuth quadruple therapy: a randomized controlled trial. Helicobacter. 2024, 29:e13079. 10.1111\/hel.13079","journal-title":"Helicobacter"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12962","article-title":"A \"new\" option in Helicobacter pylori eradication: high-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting","volume":"28","author":"Macedo Silva V","year":"2023","unstructured":"Macedo Silva V, Lima Capela T, Freitas M, Boal Carvalho P, Magalh\u00e3es J, Cotter J. A \"new\" option in Helicobacter pylori eradication: high-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting. Helicobacter. 2023, 28:e12962. 10.1111\/hel.12962","journal-title":"Helicobacter"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028323","article-title":"Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori","volume":"100","author":"Wang J","year":"2021","unstructured":"Wang J, Cao Y, He W, Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine (Baltimore). 2021, 100:e28323. 10.1097\/MD.0000000000028323","journal-title":"Medicine (Baltimore)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i27.3304","article-title":"Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: a prospective, multicenter, randomized, two-stage study","volume":"30","author":"Huang XP","year":"2024","unstructured":"Huang XP, Liu YJ, Lin SW, et al.. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: a prospective, multicenter, randomized, two-stage study. World J Gastroenterol. 2024, 30:3304-3313. 10.3748\/wjg.v30.i27.3304","journal-title":"World J Gastroenterol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002592","article-title":"Ten-day vonoprazan-amoxicillin dual therapy vs standard 14-day bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: a multicenter randomized clinical trial","volume":"119","author":"Yan TL","year":"2024","unstructured":"Yan TL, Wang JH, He XJ, et al.. Ten-day vonoprazan-amoxicillin dual therapy vs standard 14-day bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: a multicenter randomized clinical trial. Am J Gastroenterol. 2024, 119:655-661. 10.14309\/ajg.0000000000002592","journal-title":"Am J Gastroenterol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1049908","article-title":"Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study","volume":"13","author":"Hu Y","year":"2022","unstructured":"Hu Y, Xu X, Liu XS, et al.. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2022, 13:1049908. 10.3389\/fimmu.2022.1049908","journal-title":"Front Immunol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13118","article-title":"Vonoprazan-amoxicillin dual therapy with different amoxicillin administration regimens for Helicobacter pylori treatment: a randomized controlled trial","volume":"29","author":"Qiu S","year":"2024","unstructured":"Qiu S, Huang Y, Chen J, et al.. Vonoprazan-amoxicillin dual therapy with different amoxicillin administration regimens for Helicobacter pylori treatment: a randomized controlled trial. Helicobacter. 2024, 29:e13118. 10.1111\/hel.13118","journal-title":"Helicobacter"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2024.2407898","article-title":"Eradication rate and safety of vonoprazan-amoxicillin dual therapy for helicobacter pylori eradication: a randomized controlled trial","volume":"59","author":"Jiang G","year":"2024","unstructured":"Jiang G, Luo M, Zheng P, Cong Y, Feng Y, Zhou F. Eradication rate and safety of vonoprazan-amoxicillin dual therapy for helicobacter pylori eradication: a randomized controlled trial. Scand J Gastroenterol. 2024, 59:1229-1233. 10.1080\/00365521.2024.2407898","journal-title":"Scand J Gastroenterol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14130","article-title":"Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication","volume":"46","author":"Jung YS","year":"2017","unstructured":"Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017, 46:106-114. 10.1111\/apt.14130","journal-title":"Aliment Pharmacol Ther"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9781212","article-title":"Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials","volume":"2019","author":"Lyu QJ","year":"2019","unstructured":"Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int. 2019, 2019:9781212. 10.1155\/2019\/9781212","journal-title":"Biomed Res Int"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104661","article-title":"Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"152","author":"Guo B","year":"2021","unstructured":"Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: a systematic review and meta-analysis. Microb Pathog. 2021, 152:104661. 10.1016\/j.micpath.2020.104661","journal-title":"Microb Pathog"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.844915","article-title":"Susceptibility-guided therapy vs. bismuth-containing quadruple therapy as the first-line treatment for Helicobacter pylori infection: a systematic review and meta-analysis","volume":"9","author":"Ouyang Y","year":"2022","unstructured":"Ouyang Y, Zhang W, He C, Zhu Y, Lu N, Hu Y. Susceptibility-guided therapy vs. bismuth-containing quadruple therapy as the first-line treatment for Helicobacter pylori infection: a systematic review and meta-analysis. Front Med (Lausanne). 2022, 9:844915. 10.3389\/fmed.2022.844915","journal-title":"Front Med (Lausanne)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014396","article-title":"High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: a systematic review and meta-analysis","volume":"98","author":"Yang X","year":"2019","unstructured":"Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2019, 98:e14396. 10.1097\/MD.0000000000014396","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357993-comparison-of-vonoprazan-triple-therapy-bismuth-quadruple-therapy-and-amoxicillin-therapy-for-helicobacter-pylori-infection-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T19:58:09Z","timestamp":1745870289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357993-comparison-of-vonoprazan-triple-therapy-bismuth-quadruple-therapy-and-amoxicillin-therapy-for-helicobacter-pylori-infection-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":57,"URL":"https:\/\/doi.org\/10.7759\/cureus.83142","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}